Economic evaluation of systemic therapies for moderate to severe psoriasis

Background  New biologics have dramatically changed therapeutic options for psoriasis, albeit at additional cost.

[1]  L. Curtis,et al.  Unit Costs of Health and Social Care 2016 , 2015 .

[2]  D. Mcgibbon,et al.  Inpatient management of psoriasis: a multicentre service review to establish national admission standards , 2007, The British journal of dermatology.

[3]  J. Saurat,et al.  Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION) , 2007, The British journal of dermatology.

[4]  K. Reich,et al.  Costs and quality of life in patients with moderate to severe plaque‐type psoriasis in Germany: A multi‐center study , 2007, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[5]  M. Sculpher,et al.  Etanercept and efalizumab for the treatment of psoriasis: a systematic review. , 2006, Health technology assessment.

[6]  R. Shikiar,et al.  The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study , 2006, Health and quality of life outcomes.

[7]  D. Ford,et al.  Work Limitations and Productivity Loss Are Associated with Health-Related Quality of Life but Not with Clinical Severity in Patients with Psoriasis , 2006, Dermatology.

[8]  S. Feldman,et al.  Cost-effectiveness of moderate-to-severe psoriasis treatment , 2006, Expert opinion on pharmacotherapy.

[9]  A. Gottlieb,et al.  Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy , 2006, The Journal of dermatological treatment.

[10]  S. Feldman,et al.  The negative impact of psoriasis on the workplace , 2006, The Journal of dermatological treatment.

[11]  S. Feldman,et al.  Adverse events from systemic therapies for psoriasis are common in clinical practice , 2006, The Journal of dermatological treatment.

[12]  A. Finlay,et al.  British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005 , 2005, The British journal of dermatology.

[13]  M. Augustin,et al.  Cost‐of‐illness in patients with moderate and severe chronic psoriasis vulgaris in Germany , 2005, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[14]  J. Koo,et al.  Update on the mechanisms and efficacy of biological therapies for psoriasis. , 2005, Journal of dermatological science.

[15]  D. Symmons,et al.  Guideline for anti-TNF-α therapy in psoriatic arthritis , 2005 .

[16]  S. Feldman,et al.  The impact of biologics on the quality of life of psoriasis patients and the economics of psoriasis care. , 2005, Seminars in cutaneous medicine and surgery.

[17]  G. Lu,et al.  Combination of direct and indirect evidence in mixed treatment comparisons , 2004, Statistics in medicine.

[18]  A. Gottlieb,et al.  Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. , 2004, Journal of the American Academy of Dermatology.

[19]  J. Saurat,et al.  Biological therapies in the systemic management of psoriasis: International Consensus Conference , 2004, The British journal of dermatology.

[20]  R. Stern.  Inpatient hospital care for psoriasis: a vanishing practice in the United States. , 2003, Journal of the American Academy of Dermatology.

[21]  P. Bossuyt,et al.  Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. , 2003, The New England journal of medicine.

[22]  Anna Rodgers.  The National Institute for Clinical Excellence (NICE) , 2002, Annals of the rheumatic diseases.

[23]  Ezekiel J Emanuel,et al.  Quantifying the harmful effect of psoriasis on health-related quality of life. , 2002, Journal of the American Academy of Dermatology.

[24]  Griffiths,et al.  Intermittent short courses of cyclosporin (Neoral®) for psoriasis unresponsive to topical therapy: a 1‐year multicentre, randomized study , 1999 .

[25]  Munro,et al.  The value of in‐patient dermatology: a survey of in‐patients in Scotland and northern England , 1999, The British journal of dermatology.

[26]  P. Dolan,et al.  Modeling valuations for EuroQol health states. , 1997, Medical care.

[27]  S. Feldman,et al.  The economic impact of psoriasis increases with psoriasis severity. , 1997, Journal of the American Academy of Dermatology.

[28]  D. Feeny,et al.  Utilities and Quality-Adjusted Life Years , 1989, International Journal of Technology Assessment in Health Care.

[29]  B. Strober,et al.  Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. , 2008, Journal of the American Academy of Dermatology.

[30]  D. Symmons,et al.  Guideline for anti-TNF-alpha therapy in psoriatic arthritis. , 2005, Rheumatology.

[31]  Methodology for the 2004 Annual Survey of Hours and Earnings , 2004 .

[32]  V. Ho,et al.  Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. The PISCES Study Group. , 1999, The British journal of dermatology.

[33]  T Fredriksson,et al.  Severe psoriasis--oral therapy with a new retinoid. , 1978, Dermatologica.